CancerDrs

Breast Cancer clinical trials in New Hampshire

11 actively recruiting breast cancer trials at 7 sites across New Hampshire.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in New Hampshire:
  • New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center — Lebanon, New Hampshire
  • Solinsky Center for Cancer Care — Manchester, New Hampshire
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…

Sponsor: AstraZeneca
NCT ID: NCT05774951
Sites in New Hampshire:
  • Research Site — Laconia, New Hampshire
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has sprea…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03606967
Sites in New Hampshire:
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center — Lebanon, New Hampshire
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

There are two parts to this study. It is a phase 1b followed by a randomized phase 2 study to assess whether adding 3 years of adjuvant tetrathiomolybdate (TM) to standard 6 months treatment of adjuvant capecitabine and pembrolizumab in hi…

Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT06134375
Sites in New Hampshire:
  • Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.

Sponsor: OncoTherapy Science, Inc.
NCT ID: NCT02926690
Sites in New Hampshire:
  • Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
View on ClinicalTrials.gov →
Phase 4 Recruiting Industry

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor…

Sponsor: AstraZeneca
NCT ID: NCT07357597
Sites in New Hampshire:
  • Research Site — Lebanon, New Hampshire
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Testing a Mammography Decision Intervention in a Rural Setting

The overall objective of this COBRE pilot project is to enhance the design of a 3-arm cluster randomized trial that will test the efficacy and mechanism of effect of the MyMammogram DA with or without a provider communication intervention.…

Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT06522568
Sites in New Hampshire:
  • Cheshire Medical Center — Keene, New Hampshire
  • New London Hospital Primary Care — New London, New Hampshire
  • Newport Health Center — Newport, New Hampshire
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation

The goal of this clinical trial is to test the effect of an affect-based exercise prescription on moderate-vigorous physical activity participation among survivors of breast cancer who completed primary treatment within the last 5 years. T…

Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT06258993
Sites in New Hampshire:
  • Dartmouth-Hitchcock Clinic — Lebanon, New Hampshire
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Pilot SMART of a Remotely Delivered, Physical Activity Intervention for Breast Cancer Survivors

The goal of this clinical trial is to evaluate the feasibility of randomizing participants to a "step-up" intervention pathway when they perform \<150 minutes of MVPA at the 6-week data collection burst. Participants who performed \<150 mi…

Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT07706556
Sites in New Hampshire:
  • Dartmouth-Hitchcock Clinic — Lebanon, New Hampshire
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07